US6129761A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Injectable hydrogel compositions
Assignee: Reprogenesis Inc
•
Filing: 1995-06-07
•
Granted: 2000-10-10
•
Expires: 2015-06-07
Abstract
Abstract Slowly polymerizing hydrogels are provided which are useful as a means of delivering large numbers of isolated cells via injection. The gels promote engraftment and provide three dimensional templates for new cell growth. The resulting tissue is similar in composition and histology to naturally occurring tissue. This method can be used for a variety of reconstructive procedures, including custom molding of cell implants to reconstruct three dimensional tissue defects, as well as implantation of tissues generally. The polymers permit construction of muscle and cartilage tissues which are useful to repair defects such as reflux and incontinence.
Inventors
- 👤 Jeffrey A. Hubbell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 22:18
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61F; A61F2/00; A61L27/3839; A61L27/50; A61L27/52; C; C12; C12N; C12N5/00; C12N5/0068; C12N2533/00; C12N2533/70
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
97 words
A method for making and implanting a cell-hydrogel suspension into an animal comprising mixing dissociated cells with a solution comprising a biocompatible polymer capable of crosslinking to form a hydrogel to form a cell-polymer suspension, wherein the polymer is selected from the group consisting of (a) modified hyaluronic acids, (b) synthetic modified alginates, (c) polymers which are covalently crosslinkable by a radical reaction and (d) polymers which gel by exposure to monovalent ions; implanting the suspension into the animal; and permitting the biocompatible polymer to crosslink and form a hydrogel matrix having the dissociated cells dispersed therein.
Claim 2
Independent Claim
97 words
A method for making and implanting a cell-hydrogel suspension into an animal comprising mixing dissociated cells with a solution comprising a biocompatible polymer capable of crosslinking to form a hydrogel to form a cell-polymer suspension, wherein the polymer is selected from the group consisting of (a) modified hyaluronic acids, (b) synthetic modified alginates, (c) polymers which are covalently crosslinkable by a radical reaction and (d) polymers which gel by exposure to monovalent ions; implanting the suspension into the animal; and permitting the biocompatible polymer to crosslink and form a hydrogel matrix having the dissociated cells dispersed therein.
Claim 3
Dependent Claim
19 words
The method of claim 1 wherein the hydrogel matrix containing the dissociated cells forms before the suspension is implanted.
Claim 4
Dependent Claim
39 words
The method of claim 1 wherein the suspension of the biocompatible polymer and the dissociated cells is injected into the animal as a cell suspension; and wherein the hydrogel matrix containing the cells forms after the mixture is injected.
Claim 5
Dependent Claim
23 words
The method of claim 1 wherein the biocompatible polymer is selected from the group consisting of modified alginates and a modified hyaluronic acid.
Claim 6
Dependent Claim
30 words
The method of claim 1 wherein the hydrogel is formed by exposure of the polymer to a crosslinking agent selected from the group consisting of ions, radical initiators, and enzymes.
Claim 7
Dependent Claim
22 words
The method of claim 1 wherein the biocompatible polymer is a polysaccharide which forms a hydrogel upon exposure to a monovalent cation.
Claim 8
Dependent Claim
21 words
The method of claim 6 wherein the polymer is a polysaccharide which forms a hydrogel upon exposure to a monovalent cation.
Claim 9
Dependent Claim
11 words
The method of claim 6 wherein the monovalent cation is sodium.
Claim 10
Dependent Claim
54 words
The method of claim 5 wherein the biocompatible polymer comprises substituents capable of crosslinking by a radical reaction in the presence of a radical initiator to form a hydrogel, and wherein the biocompatible polymer is contacted with the radical initiator thereby to covalently crosslink the polymer by a radical reaction and form the hydrogel.
Claim 11
Dependent Claim
23 words
The method of claim 9 wherein the radical initiator is selected from the group consisting of a dye, ultraviolet light and visible light.
Claim 12
Dependent Claim
30 words
The method of claim 1 wherein the dissociated cells are selected from the group consisting of cells that form cartilage, cells that form bone, muscle cells, fibroblasts, and organ cells.
Claim 13
Dependent Claim
18 words
The method of claim 2 wherein the hydrogel is molded to form a specific shape prior to implantation.
Claim 14
Dependent Claim
27 words
The method of claim 3 wherein the hydrogel is molded to form a specific shape after mixing with the dissociated cells and being implanted into the animal.
Claim 15
Dependent Claim
9 words
The method of claim 1 for treating vesicoureteral reflux.
Claim 16
Dependent Claim
8 words
The method of claim 1 for treating incontinence.
Claim 17
Dependent Claim
16 words
The method of claim 1 for treating a defect in a patient within the thoracic region.
Claim 18
Dependent Claim
14 words
The method of claim 1 for treating a patient within the upper gastrointestinal tract.
References Cited (Backward Citations)
US1995970A
Cited
US2609347A
Cited
US2664366A
Cited
US2664367A
Cited
US2659935A
Cited
US2653917A
Cited
US2676945A
Cited
US2683136A
Cited
US2703316A
Cited
US2758987A
Cited
US2846407A
Cited
US2951828A
Cited
US3531561A
Cited
US3880991A
Cited
US4069307A
Cited
US3935065A
Cited
US3960150A
Cited
US4026304A
Cited
US3883393A
Cited
US3826241A
Cited
US4021382A
Cited
US4450150A
Cited
US3974526A
Cited
US3992725A
Cited
US3902497A
Cited
US4192827A
Cited
US3995444A
Cited
US3949073A
Cited
US4144126A
Cited
US4060081A
Cited
US4280954A
Cited
US4186448A
Cited
US4391797A
Cited
US4141087A
Cited
US4328204A
Cited
US4206399A
Cited
US4137921A
Cited
DE2853614A1
Cited
US4304591A
Cited
US4277582A
Cited
US4228243A
Cited
US4239664A
Cited
US4243775A
Cited
US4456687A
Cited
US4713070A
Cited
US4352883A
Cited
US4304866A
Cited
US4444887A
Cited
US4348329A
Cited
US4356261A
Cited
US4347847A
Cited
US4427808A
Cited
US4563490A
Cited
US4576608A
Cited
US4675189A
Cited
US4416986A
Cited
US4553272A
Cited
US4546500A
Cited
US4438198A
Cited
US4431428A
Cited
US4446234A
Cited
US4505266A
Cited
US4458678A
Cited
US4485096A
Cited
US4439152A
Cited
US4545082A
Cited
US4520821A
Cited
US4528265A
Cited
US4485097A
Cited
US4494385A
Cited
US4495174A
Cited
US4440921A
Cited
US4489056A
Cited
US4544516A
Cited
US4559304A
Cited
US4808353A
Cited
US4645669A
Cited
US4559298A
Cited
US4446229A
Cited
US4642120A
Cited
US4689293A
Cited
EP0153896B1
Cited
US4609551A
Cited
US4891225A
Cited
US4778749A
Cited
US4675284A
Cited
US4757017A
Cited
US4637931A
Cited
US4563350A
Cited
US4595713A
Cited
US4868121A
Cited
DE3518150C1
Cited
US4627853A
Cited
US4681763A
Cited
US4902295A
Cited
US4853324A
Cited
EP0226061B1
Cited
US4721096A
Cited
US4880622A
Cited
EP0248246B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-10-10 | 2004-04-10 | 2004-10-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-10-10 | 2008-04-10 | 2008-10-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-10-10 | 2012-04-10 | 2012-10-10 | $7700.00 | Window Closed / Lapsed |